|
|
Article: Biovail to Purchase Rights to Develop and Commercialize JP-1730/Fipamezole in North America.
- Article from:
- Health & Beauty Close-Up
- Article date:
- August 25, 2009
CopyrightCOPYRIGHT 2009 Close-Up Media, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Biovail Corp. announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland), a subsidiary of Santhera Pharmaceuticals Holding AG, to acquire the U.S. and Canadian rights to develop and commercialize Santhera's JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson's Disease (DPD).
In a release, the Company noted:
JP-1730/ fipamezole is a compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.
Bill Wells, Biovail's Chief Executive Officer said, "This agreement with Santhera is directly on strategy ...